Loading data for CLLS — first visit, this takes a few seconds.
Cellectis S.A. (CLLS)
NasdaqGM: CLLS
· Real-Time Price · USD
3.40
-0.11 (-3.13%)
At close: Aug 28, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Cellectis S.A. (CLLS) Stock Price, Analysis & Data
-3.13% (1D)
No data available
| Bid | 2.8 |
| Market Cap | 342.38M |
| Revenue (ttm) | 63.82M |
| Net Income (ttm) | -65.31M |
| 2.75 | |
| -0.64 | |
| n/a | |
| -5.48 | |
| P/B (ttm) | 6.02 |
| P/S (ttm) | 5.36 |
| Earnings Date | Nov 13, 2026 |
| Ask | 2.99 |
| Volume | 5,600 |
| Avg. Volume (20D) | 28,304 |
| Open | 3.48 |
| Previous Close | 3.51 |
| Day's Range | 3.40 - 3.57 |
| 52-Week Range | 2.35 - 5.48 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLLS
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, design...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 24, 2015
Employees 224
Stock Exchange NasdaqGM
Ticker Symbol CLLS
Website https://www.cellectis.com
Financial Performance
In 2025, Cellectis S.A.'s revenue was 72.95M, an increase of 75.76% compared to the previous year's 41.51M. Earnings were -67.59M, an increase of 83.87%.
Financial StatementsEarnings Surprise
Cellectis S.A. has released their quarterly earnings on Aug 6, 2026:
- Revenue of $5.23M misses estimates by $0, with -68.74% YoY decline.
- EPS of -0.22 exceeds estimates by 0.03, with 0.00% YoY growth.
Cellectis S.A. is scheduled to release its earnings on Nov 13, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2